Pacritinib
Near Add Your Location
Accepting patients
Decitabine Plus a JAK-Inhibitor
A Phase 2 Trial Investigating Decitabine in Combination With a JAK-Inhibitor as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated/Blast Phase Myeloproliferative Neoplasms
- Hypomethylating Agents (HMA)
- JAK1 Inhibitor
- JAK2 Inhibitor
- Phase 2
Not yet accepting
Pacritinib
Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
- Kinase Inhibitor
- Phase 1/2